期刊文献+

利拉鲁肽致不良反应文献分析 被引量:11

Literature analysis of adverse drug reactions induced by liraglutide
原文传递
导出
摘要 目的:探讨利拉鲁肽致不良反应的发生规律和特点,为临床合理用药提供依据。方法:检索自2010年至2019年中CNKI、万方、VIP、PubMed,Web of Science等数据库的国内外文献,进行整理分析。结果:总共收集16例不良反应,男性10例,女性6例,以50岁以上患者发生率较高(11例,68.75%)。不良反应多发生于6个月内,累及多个组织/器官,以消化系统损害(31.25%)、皮肤及附件系统损害(18.75%)以及肝胆系统损害(18.75%)为主。结论:临床中使用利拉鲁肽要加强用药监护,密切防范ADR的发生,尤其对于老年患者、肝肾功能不全及既往存在药物过敏史的患者。 OBJECTIVE To explore the general regularity and characteristics of adverse reactions induced by liraglutide,and to provide reference for rational drug use in clinic.METHODS The domestic and foreign literatures of CNKI,Wanfang,VIP,PubMed and Web of Science from 2010 to 2019 were searched and analyzed.RESULTS A total of 16 adverse reactions were collected,including 10 males and 6 females.The incidence of adverse reactions was higher in patients over 50 years old(11 cases,68.75%).Adverse reactions mostly occurred within 6 months,involving multiple tissues/organs,mainly digestive system disorders(31.25%),skin and appendages disorders(18.75%)and hepatobiliary system disorders(18.75%).CONCLUSION Clinicians should pay more attention to the safety monitoring of liraglutide,especially in elder patients,patients with liver and kidney insufficiency and allergic history.
作者 董士超 刘鸿杉 王靖宇 蔡磊 王荣环 DONG Shi-chao;LIU Hong-shan;WANG Jing-yu;CAI Lei;WANG Rong-huan(Department of Pharmacy,Second Hospital Affiliated to Tianjin Medical University,Tianjin 300211,China;Tianjin Municipal Inspection Bureau for Health and Family Planning,Tianjin 300070,China;Tianjin Medical University Metabolic Diseases Hospital,Tianjin 300070,China;Department of Pharmacy,Tianjin Third Central Hospital,Tianjin 300170,China)
出处 《中国医院药学杂志》 CAS 北大核心 2020年第3期310-314,348,共6页 Chinese Journal of Hospital Pharmacy
基金 国家自然科学基金(编号:81603461).
关键词 利拉鲁肽 不良反应 文献分析 liraglutide adverse reactions literature analysis
  • 相关文献

参考文献6

二级参考文献45

  • 1Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial ( LEAD-6 ). I,anet, 2009,374 : 39-47. 被引量:1
  • 2Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes ( LEAD-3 Mono) : a randomised, 52- week, phase III, double-blind, parallel treatment trial. Lancet, 2009, 373:473481. 被引量:1
  • 3Femke B, Arjan JV, Michaela D, et al. Vesiculopustular dermatosis: An uncommon side-effect of liraglutide? J Diabetes Complications, 2012,26:458-459. 被引量:1
  • 4Toft-Nielsen MB,Damholt MB,Madsbad S. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients[J].Journal of Clinical Endocrinology and Metabolism,2001.3717-3723. 被引量:1
  • 5Vilsboll T,Agerso H,Krarup T. Similar elimination rotes of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects[J].Journal of Clinical Endocrinology and Metabolism,2003.220-224. 被引量:1
  • 6Degn KB,Juhl CB,Sturis J. One week's treatment with the longacting glucagon-like peptide 1 derivative liraglutide (NN2211)markedly improves 24-h glycemia and alpha-and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes[J].Journal of Diabetes,2004.1187-1194. 被引量:1
  • 7Mari A,Sallas WM,He YL. Vildagliptin,a dipeptidyl peptidase-Ⅳ inhibitor,improves model-assessed beta-cell function in patients with type 2 diabetes[J].Journal of Clinical Endocrinology and Metabolism,2005.4888-4894. 被引量:1
  • 8Barragan JM,Rodriguez RE,Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36)amide in rats[J].American Journal of Physiology,1994.E459-E466. 被引量:1
  • 9Yamamoto H,Lee CE,Marcus JN. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons[J].Journal of Clinical Investigation,2002.43-52. 被引量:1
  • 10Robinson LE,Holt TA,Rees K. Effects of exenatide and liraglutide on heart rate,blood pressure and body weight:systematic review and meta-analysis[J].BMJ Open,2013,(01). 被引量:1

共引文献50

同被引文献113

引证文献11

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部